Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · Real-Time Price · USD
7.90
-0.38 (-4.53%)
Oct 31, 2024, 4:00 PM EDT - Market closed
Lexeo Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Lexeo Therapeutics stock have an average target of 22.14, with a low estimate of 19 and a high estimate of 28. The average target predicts an increase of 180.25% from the current stock price of 7.90.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for LXEO stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 3 | 3 | 3 | 3 | 3 |
Buy | 3 | 4 | 4 | 4 | 4 | 4 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 5 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $21 | Strong Buy | Reiterates | $21 | +165.82% | Oct 31, 2024 |
Chardan Capital | Chardan Capital | Strong Buy Maintains $23 | Strong Buy | Maintains | $23 | +191.14% | Oct 30, 2024 |
Chardan Capital | Chardan Capital | Strong Buy Maintains $23 | Strong Buy | Maintains | $23 | +191.14% | Oct 25, 2024 |
Chardan Capital | Chardan Capital | Strong Buy Maintains $23 | Strong Buy | Maintains | $23 | +191.14% | Aug 14, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $22 → $21 | Strong Buy | Maintains | $22 → $21 | +165.82% | Aug 13, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.82
from -12.40
EPS Next Year
-3.08
from -2.82
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | n/a | n/a | n/a | ||
Avg | n/a | n/a | n/a | ||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -2.68 | -2.76 | -2.37 | ||
Avg | -2.82 | -3.08 | -3.33 | ||
Low | -2.95 | -3.76 | -4.43 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.